Want to see JP:4888 full AI Analyst Report?

STELLA PHARMA CORPORATION (4888) Price & Analysis

0 Followers

4888 Stock Chart & Stats

¥203.00

-¥14.00(-2.68%)

At close: Jan 08 4:00 PM EST

¥203.00

-¥14.00(-2.68%)

Day’s Range― - ―

52-Week Range¥200.00 - ¥995.00

Previous CloseN/A

Volume163.70K

Average Volume (3M)332.29K

Market Cap

¥11.03B

Enterprise Value¥9.93B

Total Cash (Recent Filing)¥2.82B

Total Debt (Recent Filing)¥747.14M

Price to Earnings (P/E)―

Beta0.99

Next Earnings

Aug 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-22.94

Shares Outstanding36,034,100

10 Day Avg. Volume566,500

30 Day Avg. Volume332,290

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)10.64

Price to Sales (P/S)79.85

P/FCF Ratio-74.78

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginsSustained gross margins near 77%–90% indicate strong product-level economics or pricing power typical of specialty pharma. Over 2–6 months this supports unit profitability potential and gives room to cover R&D or SG&A if top-line stabilizes, improving long-term operating leverage.

Manageable LeverageLower recent debt-to-equity implies a more conservative capital structure versus historic peaks. Manageable leverage reduces near-term solvency risk, preserves borrowing capacity for development or commercialization, and affords flexibility to absorb revenue shocks without immediate refinancing.

Proved Cash Generation EpisodePositive operating and free cash flow in 2025 shows the business can generate cash under favorable conditions. This demonstrates an attainable cash-generative state that, if recaptured, would lessen funding dependence and support reinvestment in trials or commercialization over the medium term.

Bears Say

Structural UnprofitabilityDeep negative net margins reflect persistent operating losses that erode equity and constrain reinvestment. Over months this limits the company's ability to self-fund R&D or commercialization, increases reliance on external capital, and weakens resilience to further revenue shocks.

Sharp Revenue DeclineA ~67% revenue drop in 2026 signals material demand or commercialization setbacks and creates severe visibility issues. Such volatility impairs planning, prevents scaling fixed-cost absorption, and raises execution risk for product launches or partnerships over the coming months.

Inconsistent Cash GenerationRecurring negative free cash flow across multiple years indicates periodic cash burn and likely dependence on financing. This pattern increases dilution or refinancing risk, constrains strategic investments, and makes funding contingency planning a persistent governance and liquidity issue.

4888 FAQ

What was STELLA PHARMA CORPORATION’s price range in the past 12 months?

STELLA PHARMA CORPORATION lowest stock price was ¥200.00 and its highest was ¥995.00 in the past 12 months.

What is STELLA PHARMA CORPORATION’s market cap?

STELLA PHARMA CORPORATION’s market cap is ¥11.03B.

When is STELLA PHARMA CORPORATION’s upcoming earnings report date?

STELLA PHARMA CORPORATION’s upcoming earnings report date is Aug 13, 2026 which is in 18 days.

How were STELLA PHARMA CORPORATION’s earnings last quarter?

STELLA PHARMA CORPORATION released its earnings results on May 13, 2026. The company reported -¥7.9 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.9.

Is STELLA PHARMA CORPORATION overvalued?

According to Wall Street analysts STELLA PHARMA CORPORATION’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does STELLA PHARMA CORPORATION pay dividends?

STELLA PHARMA CORPORATION does not currently pay dividends.

What is STELLA PHARMA CORPORATION’s EPS estimate?

STELLA PHARMA CORPORATION’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does STELLA PHARMA CORPORATION have?

STELLA PHARMA CORPORATION has 36,034,100 shares outstanding.

What happened to STELLA PHARMA CORPORATION’s price movement after its last earnings report?

STELLA PHARMA CORPORATION reported an EPS of -¥7.9 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.132%.

Which hedge fund is a major shareholder of STELLA PHARMA CORPORATION?

Currently, no hedge funds are holding shares in JP:4888

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

STELLA PHARMA CORPORATION

Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture therapy (BNCT). Their product lineup includes SPM-011, a boron-containing drug designed for BNCT, which is utilized in the treatment of head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma, and angiosarcoma. Founded in 2007, Stella Pharma Corporation maintains its headquarters in Osaka, Japan.